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BACKGROUND AND PURPOSE
P2Y1, P2Y2, P2Y4, P2Y12 and P2Y13 receptors for nucleotides have been reported to mediate presynaptic inhibition, but
unequivocal evidence for facilitatory presynaptic P2Y receptors is not available. The search for such receptors was the purpose
of this study.
EXPERIMENTAL APPROACH
In primary cultures of rat superior cervical ganglion neurons and in PC12 cell cultures, currents were recorded via the
perforated patch clamp technique, and the release of [3H]-noradrenaline was determined.
KEY RESULTS
ADP, 2-methylthio-ATP and ATP enhanced stimulation-evoked 3H overﬂow from superior cervical ganglion neurons, treated
with pertussis toxin to prevent the signalling of inhibitory G proteins. This effect was abolished by P2Y1 antagonists and by
inhibition of phospholipase C, but not by inhibition of protein kinase C or depletion of intracellular Ca2+ stores. ADP and a
speciﬁc P2Y1 agonist caused inhibition of Kv7 channels, and this was prevented by a respective antagonist. In neurons not
treated with pertussis toxin, 3H overﬂow was also enhanced by a speciﬁc P2Y1 agonist and by ADP, but only when the P2Y12
receptors were blocked. ADP also enhanced K+-evoked 3H overﬂow from PC12 cells treated with pertussis toxin, but only in a
clone expressing recombinant P2Y1 receptors.
CONCLUSIONS AND IMPLICATIONS
These results demonstrate that presynaptic P2Y1 receptors mediate facilitation of transmitter release from sympathetic neurons
most likely through inhibition of Kv7 channels.
Abbreviations
2-MeSATP, 2-methylthio-ATP; DMSO, dimethyl sulphoxide; H-7, 1-(5-isoquinolinylsulphonyl)-2-methylpiperazine;
IM, M-type K+ current; MRS 2179, 2′-deoxy-N6-methyladenosine 3′,5′-bisphosphate tetrasodium salt; MRS 2365,
[[(1R,2R,3S,4R,5S)-4-[6-amino-2-(methylthio)-9H-purin-9 -yl]-2,3-dihydroxybicyclo[3.1.0]hex-1-yl]methyl] diphosphoric
acid mono ester trisodium salt; PIP2, phosphatidylinositol 4,5-bisphosphate; PTX, pertussis toxin; SCG, superior cervical
ganglion; TTX, tetrodotoxin; U73122, 1-[6-[((17b)-3-methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]-1H-pyrrole-2,
5-dione
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ATP is released together with noradrenaline from sympa-
thetic nerve terminals and contributes to the sympatho-
effector transmission (von Kugelgen and Starke, 1991). This
neurotransmission is tightly controlled by a large number of
different presynaptic receptors, which also include autorecep-
tors for noradrenaline as well as nucleotides (Boehm and
Kubista, 2002). Amongst the members of the adrenoceptor
family, presynaptic a2A and a2C receptors mediate autoinhibi-
tion of noradrenaline release, whereas b2 receptors mediate
facilitation (Boehm and Kubista, 2002). Within the family of
P2 receptors, ionotropic P2X receptors mediate facilitation of
transmitter release, whereas metabotropic P2Y receptors were
found to mediate inhibition only (Sperlagh et al., 2007; Dor-
ostkar and Boehm, 2008; Goncalves and Queiroz, 2008). In
this respect, the family of P2Y receptors appear to differ from
other GPCRs: most neurotransmitters and/or mediators, such
as acetylcholine, adenosine, histamine, noradrenaline and
prostaglandins are known to cause presynaptic inhibition as
well as facilitation of sympathetic transmitter release, the two
opposing actions being mediated by two different GPCRs
(Boehm and Kubista, 2002). In general, presynaptic GPCRs
linked to Gs or Gq type G-proteins mediate facilitation of
noradrenaline release, whereas receptors linked to Gi/o-
proteins mediate inhibition, although there are exceptions to
this rule (Kubista and Boehm, 2006).
Within the family of G-protein-coupled P2Y receptors, at
least eight different subtypes have been identiﬁed (P2Y1,
P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14). In heterologous
expression systems, all P2Y receptor subtypes, with the excep-
tion of P2Y12, couple to PLC via Gq and mediate increases in
inositol phosphates; via Gi/o, P2Y12, P2Y13 and P2Y14 mediate
inhibition, while P2Y11 mediates activation of adenylyl cycla-
ses (Abbracchio et al., 2006; Burnstock, 2006). Accordingly,
one might expect all P2Y but P2Y12 receptors to act as facili-
tatory presynaptic P2Y receptors. However, with respect to
the sub-classiﬁcation of presynaptic P2Y receptors, the infor-
mation available is limited, as most subtype selective ligands
have been developed quite recently (Jacobson and Boey-
naems, 2010). In fact, P2Y1, P2Y2, P2Y4, P2Y12 and P2Y13 recep-
tors have all been implicated in the presynaptic inhibition of
transmitter release, but unequivocal evidence for facilitatory
presynaptic P2Y receptors is lacking (Goncalves and Queiroz,
2008).
In sympathetically innervated tissues, such as the rat
vas deferens, ADP and 2-methylthio-ADP inhibit [
3H]-
noradrenaline release, and this is prevented by
2-methylthio-AMP, an antagonist at P2Y12 and P2Y13 recep-
tors (Queiroz et al., 2003) Likewise, in PC12 cells and rat
superior cervical ganglion (SCG) neurons, inhibitory presyn-
aptic P2Y receptors were blocked by 2-methylthio-AMP and
by the P2Y12 antagonist cangrelor (Kulick & von Kugelgen,
2002; Lechner et al., 2004). More recently, P2Y12 together
with P2Y1 receptors were shown to mediate autoinhibition
in sympathetically innervated tissues (Quintas et al., 2009).
Along the same line, evidence has been presented that P2Y1,
P2Y12 and P2Y13 receptors mediate inhibition of noradrena-
line release in the central nervous system (Csolle et al.,
2008; Heinrich et al., 2008). For this study, rat SCG neurons
in primary cell culture as well as PC12 cells were used to
search for facilitatory presynaptic P2Y receptors. The results
reveal that activation of presynaptic P2Y1 receptors leads to
an increase in sympathetic transmitter release through
activation of PLC.
Methods
Cell cultures
Primary cultures of dissociated SCG neurons from neonatal
rats were prepared as described previously (Boehm, 1999).
Newborn Sprague–Dawley rats were kept and killed 3 to 10
days after birth by decapitation in full accordance with all
rules of the Austrian animal protection law and the Austrian
animal experiment bylaws. Ganglia were removed immedi-
ately after decapitation of the animals, cut into three to four
pieces and incubated in collagenase (1.5 mg·mL
-1; Sigma,
Vienna, Austria) and dispase (3.0 mg·mL
-1; Boehringer Man-
nheim, Vienna, Austria) for 20 min at 36°C. Subsequently,
they were further incubated in trypsin (0.25% trypsin; Wor-
thington, Lakewood, NJ) for 15 min at 36°C, dissociated by
trituration and resuspended in Dulbeccos modiﬁed Eagle’s
Medium (Invitrogen, Lofer, Austria) containing 2.2 g·L
-1
glucose, 10 mg·L
-1 insulin, 25 000 IU·L
-1 penicillin and
25 mg·L
-1 streptomycin (Invitrogen), 50 mg·L
-1 nerve growth
factor (R&D Systems Inc., Minneapolis, MN) and 5% fetal calf
serum (Invitrogen). Finally, all cells were seeded onto 5 mm
plastic discs for radiotracer release experiments and onto
35 mm culture dishes for electrophysiological experiments.
The cultures were stored for 4 to 8 days in a humidiﬁed 5%
CO2 atmosphere at 36°C. On days 1 and 4 after dissociation,
the medium was exchanged entirely.
PC12 cells were obtained from the European Collection of
Cell Cultures (ECACC; Salisbury, UK) and kept in OptiMEM
(Life Technologies, Vienna, Austria) supplemented with
0.2 mM L-glutamine (HyClone, Aalst, Belgium), 25 000 IU·L
-1
penicillin and 25 mg·L
-1 streptomycin (Sigma), 5% fetal calf
serum and 10% horse serum (both Life Technologies). Once
per week, cell cultures were split, and the medium was
exchanged twice weekly. To investigate the release of previ-
ously incorporated [
3H]-noradrenaline under continuous
superfusion, PC12 cells were plated onto 5 mm discs, as
described for the SCG neurons above. All tissue culture plastic
was coated with rat tail collagen (Biomedical Technologies
Inc., Stoughton, MA, USA).
PC12 cell clones stably expressing the rat P2Y1 receptor
linked to the green ﬂuorescent protein (P2Y1-GFP) were gen-
erated as described previously; here, cells of clone 8 were used
(Moskvina et al., 2003).
Determination of [
3H]-noradrenaline release
[
3H]-noradrenaline uptake and superfusion of SCG neurons
and PC12 cells was performed as described previously
(Lechner et al., 2004). The plastic discs with dissociated
neurons or PC12 cells were incubated in 0.05 mM
[
3H]-noradrenaline ((–)-[ring-2,5,6-
3H]-noradrenaline, speciﬁc
activity 1.369 TBq·mmol
-1; Perkin Elmer, Vienna, Austria) in
culture medium supplemented with 1 mM ascorbic acid at
37°C for 1 h. Thereafter, the culture discs were transferred to
small chambers and superfused with a buffer containing
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(20), HEPES (10), fumaric acid (0.5), Na-pyruvate (5.0), ascor-
bic acid (0.57) and desipramine (0.001), adjusted to pH 7.4
with NaOH. Superfusion was performed at 25°C at a rate of
about 1.0 mL·min
-1. Collection of 4 min fractions of superfu-
sate was started after a 60 min washout period during which
excess radioactivity had been removed.
Depolarization-dependent tritium overﬂow was triggered
either by 36 monophasic rectangular electrical pulses (0.5 ms,
60 mA, 66 V·cm
-1) delivered at 0.3 Hz or by the inclusion of
25 mM KCl (NaCl was reduced accordingly to maintain iso-
tonicity) in the buffer for periods of 120 s. These stimulations
were started after 72 (S1) and 92 min (S2) of superfusion.
Nucleotides and nucleotide receptor agonists or antagonists
were included in the buffer from minute 88 onwards (see
Figure 1). Tetrodotoxin (TTX), whenever appropriate, was
included in the buffer after 50 min of superfusion (i.e. 10 min
prior to the start of sample collection). The radioactivity
remaining in the cells after the completion of experiments
was extracted by immersion of the discs in 2% (v/v) perchlo-
ric acid followed by sonication. Radioactivity in extracts and
collected fractions was determined by liquid scintillation
counting (Packard Tri-Carb 2800 TR) with a counting efﬁ-
ciency of 63%. Radioactivity released in response to electrical
ﬁeld stimulation from rat sympathetic neurons after labelling
with tritiated noradrenaline under conditions similar to
those of the present study had previously been shown to
consist predominantly of the authentic transmitter and
to contain only small amounts (15%) of metabolites
(Schwartz and Malik, 1993). Hence, the outﬂow of tritium
measured in this study was assumed to reﬂect the release of
noradrenaline and not that of metabolites.
The spontaneous (unstimulated) rate of
3H efﬂux was
obtained by expressing the radioactivity retrieved during a
collection period as percentage of the total radioactivity in
the cultures at the beginning of this period. Stimulation-
evoked tritium overﬂow was calculated as the difference
between the total tritium outﬂow during and after stimula-
tion and the estimated basal outﬂow that was assumed to
follow a linear time course throughout experiments. There-
fore, basal outﬂow during periods of stimulation was assumed
to equate to the arithmetic mean of the samples preceding
and those following stimulation, respectively. Differences
between total and estimated basal outﬂow during periods of
stimulation were expressed as percentages of total radioactiv-
ity in the cultures at the onset of stimulation (% of total
radioactivity; S%). The amount of radioactivity in the cul-
tures at the beginning of each collection period is calculated
Time (min)
Solvent
Solvent 100 μM ADP
100 μM ADP
Electrical field stimulation
25 mM K
+ stimulation
P < 0.01
P < 0.001
Time (min)
Solvent
ADP
Time (min) Time (min)
Solvent
ADP
Figure 1
Enhancement of [3H]-noradrenaline release from rat SCG neurons treated with pertussis toxin by ADP. SCG cell cultures were treated with pertussis
toxin (PTX; 100 ng·mL-1 for 24 h) and were labelled with [3H]-noradrenaline and superfused. When appropriate (C and D), 0.1 mM TTX was
present from minute 50 of superfusion onwards. Subsequent to a 60 min washout period, 4 min fractions of superfusate were collected. Tritium
overﬂow was stimulated twice (S1 after 72 min and S2 after 92 min of superfusion) by 2 min exposures to either electrical pulses (A and B) or
25 mM KCl (C and D). Either 100 mM ADP or the appropriate solvent were present from minute 88 onwards, as indicated by the arrows in (A and
C). (A and C) Exemplary time courses of fractional
3H outﬂow as a percentage of the total radioactivity in the cells (n = 3). (B and D) The S2/S1
ratios of tritium overﬂow evoked by electrical stimulation (B) or 25 mM K+ (D) in the presence of either solvent or 100 mM ADP (n = 11–12); the
P-values for the statistical signiﬁcance of differences (Student’s unpaired t-test) are indicated above the bars.
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end of experiments and that retrieved during the respective
and all subsequent collection periods.
As the amount of depolarization- or drug-induced tritium
overﬂow may vary considerably between different cultures
(Scholze et al., 2002), the effects of nucleotides on
depolarization-dependent release were evaluated by deter-
mining changes in the ratio of tritium overﬂow evoked
during the two periods of electrical or K
+ stimulation (S2/S1).
When cultures had been subjected to a certain treatment (e.g.
cholera toxin or U73122), control experiments were also per-
formed in sister cultures that had not been exposed to that
treatment (i.e. remained ‘untreated’). In order to directly
compare the effects of ADP observed in the absence with
those observed in the presence of antagonists, ADP was
applied either alone or in combination with the appropriate
antagonist. As controls, either the antagonist alone or solvent
was applied. Thereafter, the S2/S1 ratio obtained with ADP
was expressed as percentage of the corresponding S2/S1 value
obtained in its absence (S2/S1, % of control).
Electrophysiology
Currents through Kv7 channels in SCG neurons, so called M
currents (IM), were determined using the perforated patch
clamp technique as described previously (Lechner et al.,
2003). Currents were recorded at room temperature (20–
24°C) from single SCG neurons in vitro using an Axopatch
200B ampliﬁer and the pCLAMP 8.0 hardware and software
(Molecular Devices, Sunnyvale, CA). Signals were low-pass
ﬁltered at 5 kHz, digitized at 10 to 50 kHz and stored on an
IBM compatible computer. Traces were analysed off-line by
the Clampﬁt 8.1 programme (Molecular Devices). Patch elec-
trodes were pulled (Flaming-Brown puller, Sutter Instru-
ments, Novato, CA) from borosilicate glass capillaries
(Science Products, Frankfurt/Main, Germany), front-ﬁlled
with a solution consisting of (mM) K2SO4 (75), KCl (55),
MgCl2 (8) and HEPES (10), adjusted to pH 7.3 with KOH.
Electrodes were then back-ﬁlled with the same solution con-
taining 200 mg·mL
-1 amphotericin B (in 0.8% DMSO), which
yielded tip resistances of 2 to 3 MW. The bathing solution
contained (mM) NaCl (140), KCl (3.0), CaCl2 (2.0), MgCl2
(2.0), glucose (20), HEPES (10), adjusted to pH 7.4 with
NaOH. TTX (0.5 mM) was included to suppress voltage-
activated Na
+ currents. ADP and all other drugs were applied
via a DAD-12 drug application device (Adams & List, West-
bury, NY), which permits a complete exchange of solutions
surrounding the cells under investigation within less than
100 ms (Boehm, 1999). To investigate IM, cells were held at a
potential of -30 mV, and three times per minute 1 s hyper-
polarizations to -55 mV were applied to deactivate the Kv7
channels; the difference between current amplitudes 20 ms
after the onset of hyperpolarizations and 20 ms prior to
re-depolarization was taken as a measure for IM. Amplitudes
obtained during the application of test drugs (b) were com-
pared with those measured before (a) and after (c) application
of these drugs by calculating 200b / (a + c) = % of control or
100 - (200b / [a + c]) = % inhibition (Boehm, 1998).
Statistics
Statistical signiﬁcance of differences between two groups was
evaluated by Student’s unpaired t-tests; when electrophysi-
ological results with nucleotides were obtained in the absence
and presence of antagonists in each cell, Student’s paired
t-tests were employed instead (Figure 6). For comparisons
between multiple groups, one-way ANOVA followed by Bon-
ferroni’s multiple comparison corrections were used. P-values
< 0.05 were considered as indicating statistical signiﬁcance.
Materials
(–)-[Ring-2,5,6-
3H]-noradrenaline was obtained from Perki-
nElmer (Vienna, Austria); amphotericin B, ADP, ATP,
2-methylthio-ATP (2-MeSATP), U73122 (1-[6-[((17b)-3-
methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]-1H-pyrrole-
2,5-dione), thapsigargin, H-7 (1-(5-isoquinolinylsulphonyl)-
2-methylpiperazine) as well as cholera and pertussis toxin
(PTX) were from Sigma; TTX from Latoxan (Rosans, France);
MRS 2179 (2′-deoxy-N6-methyladenosine 3′,5′-bisphosphate
tetrasodium salt) and MRS 2365 ([[(1R,2R,3S,4R,5S)-4-[6-
amino-2-(methylthio)-9H-purin-9-yl]-2,3-dihydroxybicyclo
[3.1.0]hex-1-yl]methyl] diphosphoric acid mono ester triso-
dium salt) were from Tocris (Bristol, UK); bulk chemicals were
from Merck (Vienna, Austria). Cangrelor was a kind gift from
The Medicines Company (Parsippany, NJ). Water-insoluble
drugs were ﬁrst dissolved in DMSO and then diluted into
buffer to yield ﬁnal DMSO concentrations of up to 0.1%,
which were also included in control solutions. At these con-
centrations, DMSO did not affect any of the parameters inves-
tigated (Lechner et al., 2003).
Results
Enhancement of stimulation-evoked
noradrenaline release from SCG neurons
treated with pertussis toxin by ADP
ADP, at a concentration of 100 mM, has been found to reduce
noradrenaline release from rat SCG neurons triggered by
30 mM K
+; however, in neurons treated with pertussis toxin
to prevent the signalling via inhibitory G-proteins, the
nucleotide tended to enhance stimulation-evoked release
(Lechner et al., 2004). Therefore, the effect of ADP was inves-
tigated in SCG cultures treated with pertussis toxin
(100 ng·mL
-1) for 24 h and labelled with [
3H]-noradrenaline.
In these experiments, 100 mM ADP clearly enhanced tritium
overﬂow triggered by electrical ﬁeld stimulation, but left
spontaneous
3H outﬂow unaltered (Figure 1A and B). The
lack of change in spontaneous outﬂow suggests that ADP did
not trigger action potential-dependent exocytosis, as does
the activation of other Gq-coupled receptors, such as B2
bradykinin receptors (Scholze et al., 2002) or M1 muscarinic
cholinoceptors (Lechner et al., 2003). To conﬁrm that the
effect of ADP was not due to enhanced action potential
ﬁring, experiments were repeated in the presence of the Na
+
channel blocker TTX (0.1 mM). As TTX prevents electrically
evoked noradrenaline release from SCG neurons (Boehm,
1999), tritium overﬂow was stimulated by exposing the cul-
tures to 25 mM KCl for 2 min. Under these conditions, ADP
also increased stimulation-evoked tritium overﬂow
(Figure 1C and D) and left the spontaneous outﬂow unal-
tered. Thus, the facilitation effect induced by ADP does not
require action potential propagation.
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noradrenaline release from pertussis
toxin-treated SCG neurons is mediated by
P2Y1 receptors
Amongst the P2Y receptors, P2Y1, P2Y12 and P2Y13 are the
primary binding sites for ADP (von Kugelgen, 2006). To dif-
ferentiate between these three, ADP, ATP and 2-MeSATP were
chosen as agonists, the latter being a preferred agonist of
P2Y1, but not of P2Y12 and P2Y13, receptors of the rat (von
Kugelgen, 2006). All these nucleotides enhanced the electri-
cally evoked
3H overﬂow from cultures treated with pertussis
toxin; from the resulting concentration–response curves,
2-MeSATP was found to be more potent than ADP and ATP,
which were about equipotent (Figure 2A). When considering
the effects of ATP at concentrations higher than 3 mM, one
must not forget the concomitant activation of P2X receptors,
which also leads to noradrenaline release from SCG neurons
(Boehm, 1999). Nevertheless, the rank order of agonist
potency 2-MeSATP > ATP = ADP indicates that P2Y1 receptors
are involved in this effect, even though the concentrations of
these nucleotides required to produce this effect were rela-
tively high.
To corroborate the results obtained with the agonistic
nucleotides, suramin, reactive blue 2 and MRS 2179 were
employed as antagonists and applied together with ADP.
While the former two block all three ADP-sensitive P2Y recep-
tors (von Kugelgen, 2006), MRS 2179 is selective for P2Y1
(Boyer et al., 1998). All three antagonists abolished the facili-
tation of tritium overﬂow induced by ADP (Figure 2B),
thereby conﬁrming that this effect was mediated by P2Y1
receptors.
Enhancement of stimulation-evoked
noradrenaline release from SCG neurons
not treated with pertussis toxin
The above data indicate that ADP has the ability to enhance
stimulation-evoked noradrenaline release when the signal-
ling via inhibitory G proteins is blocked by pertussis toxin. To
reveal whether the facilitation by ADP may also occur in
neurons with functional Gi/o proteins, experiments were
repeated in cultures not treated with PTX; 100 mM ADP
caused a signiﬁcant reduction of electrically-evoked tritium
overﬂow in these cultures (Figure 3A), as described previously
where this inhibition of noradrenaline release was suggested
to involve P2Y12 receptors (Lechner et al., 2004). Therefore,
experiments were performed in the presence of the P2Y12
antagonist cangrelor (Jacobson and Boeynaems, 2010). Can-
grelor (10 mM), when applied alone, did not cause obvious
changes in tritium outﬂow (Figure 3C). However, when ADP
was applied together with cangrelor, it caused a signiﬁcant
increase in tritium overﬂow (Figure 3C and D). Hence, the
facilitation by ADP can be observed as soon as P2Y12 receptors
are blocked.
To reveal whether this facilitatory effect of ADP is medi-
ated by P2Y1 receptors, the selective and potent P2Y1 receptor
agonist MRS2365 (Chhatriwala et al., 2004) was employed
instead of ADP. At a concentration of 0.1 mM, MRS2365 sig-
niﬁcantly enhanced electrically-evoked tritium overﬂow
P < 0.05
P < 0.001
P < 0.01
Suramin
RB2
MRS2179
ADP
Nucleotide (log M)
S
2
/
S
1
(all in μM)
Solvent
Figure 2
Pharmacological characterization of the receptor mediating the enhancement of [3H]-noradrenaline release. SCG cell cultures were treated with
pertussis toxin (PTX; 100 ng·mL-1 for 24 h) and were labelled with [3H]-noradrenaline and superfused. Subsequent to a 60 min washout period,
4 min fractions of superfusate were collected, and tritium overﬂow was evoked by electrical ﬁeld stimulation as shown in Figure 1A. (A) The
concentration-dependent increase in the S2/S1 ratio of tritium overﬂow caused by ADP, ATP or 2-MesATP (n = 6 to 13). Nucleotides used at
the concentrations indicated or the appropriate solvent were present from minute 88 onwards. (B) The increase in the S2/S1 ratio caused by the
indicated concentrations of ADP as percentage of control in the absence or presence of the indicated concentrations (in mM) of suramin (n = 8–9),
reactive blue 2 (RB2; n = 10–12) or MRS 2179 (n = 8–9). P-values for the signiﬁcance of differences between the results obtained in the absence
and presence of antagonists are indicated above the bars.
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can also be seen in cultures not treated with pertussis toxin if
either the P2Y12 antagonist cangrelor or the selective P2Y1
agonist MRS2365 is used. Nevertheless, all future experiments
were performed in cultures treated with pertussis toxin to
avoid excessive use of these speciﬁc P2Y receptor ligands.
The enhancement of stimulation-evoked
noradrenaline release from SCG neurons
by ADP involves PLC
As the facilitation by ADP was observed in cultures treated
with pertussis toxin, this effect cannot be mediated by
inhibitory G-proteins. However, the facilitation of norad-
renaline release via presynaptic GPCRs may involve stimu-
lating Gs-proteins (Kubista and Boehm, 2006). To test for
this alternative, cultures were treated not only with pertus-
sis toxin, but also with cholera toxin (100 ng·mL
-1), both for
24 h; this strategy eliminates as G-protein subunits from
primary cultures of sympathetic neurons (Boehm et al.,
1996). However, the facilitation of electrically evoked
3H
overﬂow was the same in cultures treated with pertussis
toxin only as in those treated with pertussis toxin plus
cholera toxin (Figure 4A). Thus, the facilitatory effects of
ADP do not involve Gs proteins.
Time (min)
Solvent 100 μM ADP
Solvent 0.1 μM MRS2365
10 μM cangrelor 10 μM cangrelor + 100 μM ADP
P < 0.01
P < 0.01
P < 0.01
Solvent
ADP
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Figure 3
Modulation of [
3H]-noradrenaline release from SCG neurons by ADP, MRS 2365 and cangrelor. SCG cell cultures were labelled with
[
3H]-noradrenaline and superfused. Subsequent to a 60 min washout period, 4 min fractions of superfusate were collected, and tritium overﬂow
was evoked by electrical ﬁeld stimulation as shown in Figure 1A. (A, C and E) Exemplary time courses of fractional
3H outﬂow as a percentage of
the total radioactivity in the cells (n = 3); 100 mM ADP, 10 mM cangrelor, 0.1 mM MRS 2365 or the appropriate solvent were present from minute
88 onwards as indicated by the arrows. (B) S2/S1 ratios obtained in the presence of either solvent or 100 mM ADP (n = 11). (D) S2/S1 ratios
obtained in the presence of either 10 mM cangrelor or 10 mM cangrelor plus 100 mM ADP (n = 6). (F) S2/S1 ratios obtained in the presence of either
solvent or 0.1 mM MRS 2365 (n = 12); the P-values for the statistical signiﬁcances of differences (Student’s unpaired t-test) are indicated above
the bars.
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the Gq family and thereby to PLC (Abbracchio et al., 2006).
To test for a role of these latter enzymes, cultures were treated
with 3 mM U73122, which irreversibly blocks signalling via
PLC in SCG neurons (Boﬁll-Cardona et al., 2000). In neurons
treated with U73122 and pertussis toxin, ADP failed to sig-
niﬁcantly enhance electrically evoked tritium overﬂow.
However, in sister cultures treated with pertussis toxin only,
ADP clearly caused facilitation (Figure 4B). Thus, the facilita-
tory effects of the nucleotide involve activation of PLC.
The enhancement of stimulation-evoked
noradrenaline release from SCG neurons
does not involve PKC or increases in
intracellular Ca
2+
Activation of presynaptic receptors linked to PLC can lead to
facilitation of noradrenaline release through increases in
intracellular Ca
2+ and subsequent activation of protein kinase
C (Kubista and Boehm, 2006). To test for a role of the latter
mechanism, experiments were performed in the presence and
absence of 10 mM H-7, an inhibitor of PKA, PKC and PKG,
with afﬁnities for these enzymes in the low micromolar range
(Hidaka et al., 1984). However, the facilitation of electrically-
evoked release was the same in the absence and presence of
this broad spectrum kinase inhibitor (Figure 4C).
Increases in intracellular Ca
2+ may facilitate transmitter
release independently of protein kinases (Kubista and Boehm,
2006). Therefore, the intracellular Ca
2+ stores of the SCG
neurons were depleted by the Ca
2+-ATPase inhibitor thapsi-
gargin (Boﬁll-Cardona et al., 2000), and the facilitatory effect
of ADP was assessed again. However, the facilitation of
electrically-evoked
3H overﬂow by ADP was the same whether
0.3 mM thapsigargin were present or not (Figure 4D). Hence,
the effect of ADP is independent of increases in intracellular
Ca
2+ and activation of protein kinases A, C and G.
Control
100 μM ADP
Control
Untreated Cholera tox
P < 0.001
P < 0.001
P < 0.001
P < 0.001 P < 0.01 P < 0.001
P > 0.05
P < 0.001
DMSO H-7 DMSO Thapsigargin
Untreated U73122
100 μM ADP
Control
100 μM ADP
Control
100 μM ADP
Figure 4
The enhancement of [
3H]-noradrenaline release from rat SCG neurons by ADP involves phospholipase C, but not Gs-proteins, PKC or Ca
2+-ATPase.
All SCG cell cultures were treated with pertussis toxin (PTX; 100 ng·mL
-1 for 24 h). In addition, some cultures were treated with cholera toxin or
remained otherwise untreated. Thereafter, the cultures were labelled with [3H]-noradrenaline in the absence (untreated) or presence of 3 mM
U73122 and were then superfused. Subsequent to a 60 min washout period, 4 min fractions of superfusate were collected, tritium overﬂow was
evoked by electrical ﬁeld stimulation, and ADP was applied as shown in Figure 1A. When appropriate, 10 mM H-7, 0.3 mm thapsigargin, or 0.1%
DMSO were present from minute 50 of superfusion onwards. (A) The S2/S1 ratios of tritium overﬂow in the absence (control) or presence of
100 mM ADP in either untreated or cholera toxin-treated neurons (n = 10–12). (B) The S2/S1 ratios of tritium overﬂow in the absence or presence
of 100 mM ADP in either untreated or U73122-treated neurons (n = 9). (C) The S2/S1 ratios of tritium overﬂow in the absence (control) or presence
of 100 mM ADP applied either in a solution containing DMSO, or in a solution containing H-7 (n = 9). (D) The S2/S1 ratios of tritium overﬂow
in the absence (control) or presence of 100 mM ADP applied either in a solution containing DMSO or in a solution containing thapsigargin (n =
9). P-values for the signiﬁcance of differences between the results obtained in the absence and presence of ADP are indicated above the bars;
* indicates a signiﬁcant difference versus the corresponding result obtained in untreated cultures at P < 0.05; ns indicates no signiﬁcant difference
versus results obtained in either untreated cultures (A and B) or in the presence of DMSO (C and D).
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the enhancement of stimulation-evoked
noradrenaline release from PC12 cells treated
with pertussis toxin
PC12 cells, in contrast to SCG neurons, do not express endog-
enous P2Y1 receptors (Moskvina et al., 2003), but both types
of cells do express P2Y12 and P2Y13 receptors (Lechner et al.,
2004). To investigate whether P2Y1 receptors might mediate
an enhancement of transmitter release in a neuronal back-
ground other than SCG neurons, either non-transfected PC12
cells or a PC12 cell clone stably expressing rat P2Y1-GFP
(Moskvina et al., 2003) were compared with respect to the
modulation of stimulation-evoked noradrenaline release by
ADP. In agreement with previous results (Lechner et al.,
2004), ADP (10 mM) reduced K
+-evoked tritium overﬂow from
non-transfected PC12 cells by about 50%; however, when
these cells had been treated with pertussis toxin (100 ng·mL
-1
for 24 h), ADP failed to cause any signiﬁcant change
(Figure 5A). In PC12 cells expressing P2Y1 receptors, for com-
parison, 10 mM ADP reduced
3H overﬂow by only 15% and
when the cells had been exposed to pertussis toxin ADP
caused a signiﬁcant enhancement of K
+-evoked overﬂow
(Figure 5B). Thus, the expression of P2Y1 receptors in PC12
cells is sufﬁcient to counteract the inhibition of transmitter
release induced by ADP and instead ADP enhanced the
electrically-evoked release of noradrenaline in the pertussis
toxin-treated cells.
P2Y1 receptors mediate inhibition of Kv7
channels by ADP
Recombinant P2Y1 receptors mediate inhibition of currents
through Kv7 channels (IM) in PC12 cells (Moskvina et al.,
2003). Moreover, ADP and UDP have been found to inhibit IM
in rat SCG neurons, but this effect was suggested to involve
P2Y6 receptors (Boehm, 1998). More recently, evidence has
been presented for inhibition of Kv7 channels of SCG
neurons mediated by P2Y1 receptors (Filippov et al., 2010).
Here, we re-evaluated the receptors mediating the inhibition
of Kv7 channels by ADP in SCG neurons. In line with previ-
ous results, 10 mM ADP reduced IM relaxation amplitudes, and
this effect was entirely reversible (Figure 6A). To determine
whether P2Y1 receptors might mediate this effect, ADP was
also applied in the presence of MRS 2179, which abolished
the inhibition by ADP (Figure 6A and C). To verify that the
antagonism by MRS 2179 (30 mM) was speciﬁc for the action
of ADP, 10 mM UDP was also used to inhibit IM; this latter
effect, however, remained unaltered in the presence of MRS
2179 (Figure 6D).
To conﬁrm the results obtained with the P2Y1 antagonist,
the selective P2Y1 agonist MRS 2365 was employed again. As
expected, 0.1 mM MRS 2365 also reduced IM in an entirely
reversible manner (Figure 6B), and the inhibition was the
same as that induced by 10 mM ADP (Figure 6E). Thus, in rat
SCG neurons, P2Y1 receptors, in addition to P2Y6, mediate
inhibition of Kv7 channels.
Discussion
P2Y1 receptors are widely distributed in the central and
peripheral nervous system and mediate a plethora of effects
including the modulation of voltage- and transmitter-gated
ion channels (Hussl and Boehm, 2006). However, evidence
for presynaptic P2Y1 receptors is scarce and, if available,
only favours inhibitory presynaptic P2Y1 receptors, as sug-
gested for peripheral sensory neurons (Gerevich et al.,
2004), for hippocampal neurons (Rodrigues et al., 2005;
Csolle et al., 2008), for spinal cord neurons (Heinrich et al.,
2008) and also for sympathetic neurons (Quintas et al.,
2009). In general, presynaptic P2Y receptors have been
shown to mediate inhibition, but not facilitation, of trans-
mitter release (Goncalves and Queiroz, 2008). Hence, the
results of this study provide the ﬁrst evidence for an
Control
wt P2Y1-GFP
Untreated
P < 0.01 P > 0.1
P < 0.05
P < 0.001
PTX Untreated PTX
100 μM ADP
Control
100 μM ADP
Figure 5
Enhancement of [3H]-noradrenaline release from PC12 cell expressing P2Y1 receptors by ADP. PC12 cell cultures were treated with pertussis toxin
(PTX; 100 ng·mL-1 for 24 h) or remained untreated, were labelled with [
3H]-noradrenaline and superfused. Subsequent to a 60 min washout
period, 4 min fractions of superfusate were collected. Tritium overﬂow was stimulated twice (S1 after 72 min and S2 after 92 min of superfusion)
by 2 min exposures 25 mM KCl. ADP (10 mM) was applied as shown in Figure 1B. (A) The S2/S1 ratios of tritium overﬂow from non transfected
(wild type; wt) PC12 cells in the absence (control) or presence of 10 mM ADP (n = 6). (B) The S2/S1 ratios of tritium overﬂow from PC12 cells
expressing rat P2Y1-GFP in the absence (control) or presence of 10 mM ADP (n = 6). P-values for the signiﬁcance of differences between the results
obtained in the absence and presence of ADP are indicated above the bars.
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receptors, thereby providing a demonstration of facilitatory
presynaptic P2Y receptors.
In postganglionic sympathetic neurons, multifarious evi-
dence for inhibitory and facilitatory presynaptic P2 receptors
has been presented. The pharmacological data support the
idea that the nucleotide-dependent presynaptic facilitation
involves P2X receptors, whereas the inhibition involves P2Y
receptors (Boehm and Kubista, 2002; Sperlagh et al., 2007),
most likely P2Y12 (Queiroz et al., 2003; Lechner et al., 2004).
This was corroborated in the present study, as ADP caused
inhibition of electrically-evoked noradrenaline release from
SCG neurons, which was reversed to facilitation by the P2Y12
antagonist cangrelor (Jacobson and Boeynaems, 2010). Like-
wise, in SCG neurons treated with pertussis toxin to inactivate
thesignallingcascadesofinhibitoryP2Y12andP2Y13receptors,
ADP also enhanced electrically-evoked noradrenaline release.
Moreover, this effect was observed when release was triggered
by depolarizing K
+ concentrations in the presence of TTX in
order to block action potential propagation. Thus, the site of
actionforthefacilitationoftransmitterreleasebyADPmustbe
incloseproximitytothesitesofvesicleexocytosis(i.e.mustbe
a bona ﬁde presynaptic receptor).
The presynaptic receptor mediating the facilitation of
noradrenaline release was a P2Y receptor, more precisely a
P2Y1 receptor, as indicated by the following results: (i)
2-MesATP, an agonist at rat P2Y1 receptors (Dixon, 2000)
enhanced stimulation-evoked noradrenaline release from
SCG neurons treated with pertussis toxin; (ii) 2-MesATP was
more potent than ADP as previously demonstrated for rat
P2Y1 receptors (Vohringer et al., 2000); (iii) the facilitation by
ADP was abolished by suramin and reactive blue 2, which are
both known to be P2Y1 antagonists (von Kugelgen, 2006); (iv)
the selective P2Y1 antagonist MRS 2179 (Boyer et al., 1998)
also abolished the facilitatory affect of ADP; (v) ﬁnally, the
speciﬁc P2Y1 agonist MRS 2365 (Chhatriwala et al., 2004)
enhanced stimulation-evoked noradrenaline release even
when the signalling cascades of inhibitory P2Y receptors had
not been impaired by pertussis toxin.
The ability of P2Y1 receptors to mediate facilitation of
transmitter release was also conﬁrmed using recombinant
receptors. In PC12 cells, the activation of heterologously
expressed rat P2Y1 receptors led to an increase in K
+-evoked
noradrenaline release when signalling via inhibitory GPCRs
was prevented by pertussis toxin; this effect was not observed
in the absence of P2Y1 receptors. In PC12 cells expressing
P2Y1 receptors but not treated with the bacterial toxin, ADP
caused a reduction of depolarization-evoked noradrenaline
release as it did in non-transfected PC12 cells. However, this
inhibitory effect of ADP was much more pronounced in non-
transfected PC12 cells than in cells expressing P2Y1 receptors.
This indicates that ADP simultaneously activates the facilita-
tory P2Y1 receptors and inhibitory P2Y12 or possibly P2Y13
receptors.
P2Y1 receptors are most commonly linked to phospholi-
pase C via proteins of the Gq family (Abbracchio et al., 2006).
In accordance with this notion, the PLC inhibitor U73122
abolished the facilitation by ADP, but removal of Gs proteins
by a cholera toxin treatment had no such effect. Activated
PLC employs membrane phosphatidylinositol 4,5-
bisphosphates to generate inositol trisphosphate and diacylg-
lycerol, which then mediate increases in intracellular Ca
2+
and activation of PKC, respectively (Suh and Hille, 2007).
However, none of these effects was involved in the facilita-
tion of noradrenaline release via presynaptic P2Y1 receptors,
as neither the depletion of intracellular Ca
2+ stores nor the
inhibition of a set of protein kinases including PKC were
sufﬁcient to prevent this facilitation.
Heterologously expressed P2Y1 receptors mediate inhibi-
tion of Kv7 channels in SCG neurons (Brown et al., 2000) as
well as in PC12 cells (Moskvina et al., 2003). Moreover, ADP
has been found to inhibit Kv7 channels in SCG neurons, but
it was concluded that this effect is mediated by endogenously
P < 0.001
P > 0.6
Figure 6
P2Y1 and P2Y6 receptors mediate inhibition of currents through Kv7
channels (IM) in SCG neurons. Currents were activated at -30 mV
and quantiﬁed by determining the amplitudes of the slow current
de-activation relaxations during 1 s hyperpolarizing voltage steps to
-55 mV. These IM amplitudes were determined in the presence of
ADP (10 mM), UDP (10 mM) or MRS2365 (0.1 mM) applied either
alone or together with MRS2179 (30 mM). (A) Original current traces
recorded from one neuron before, during and after the exposure to
ADP or ADP plus MRS2179. (B) Original current traces recorded from
another neuron before, during and after the exposure to MRS2365.
(C) Summarizes the inhibition of IM by ADP in the absence or pres-
ence of MRS2179 (n = 9). (D) Summarizes the inhibition of IM by UDP
in the absence or presence of MRS2179 (n = 10). (E) Summarizes the
inhibition of IM by ADP, UDP or MRS2365 (n = 6t o1 2 ) .P-values for
the signiﬁcances of differences between the results obtained in the
absence and presence of MRS2179 are indicated above the bars; **,
*** indicate signiﬁcant differences versus the inhibition by UDP at
P < 0.01 and P < 0.001, respectively.
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known to express endogenous P2Y1, P2Y2, P2Y4, P2Y12 and
P2Y13 in addition to P2Y6 receptors (Moskvina et al., 2003;
Lechner et al., 2004). The present results clearly show that
endogenous P2Y1 receptors contribute to the regulation of
Kv7 channels in SCG neurons by nucleotides, as the inhibi-
tion by ADP was abolished by the selective P2Y1 antagonist
MRS 2179 (Boyer et al., 1998) and mimicked by the speciﬁc
P2Y1 agonist MRS 2365 (Chhatriwala et al., 2004). The inhi-
bition of IM by UDP, in contrast, was not altered by MRS 2179,
thus indicating that P2Y1 and P2Y6 receptors can control Kv7
channels independently of each other. While this work was
in progress, an inhibition of Kv7 channels in rat SCG neurons
by MRS 2365 via endogenous P2Y1 receptors has been
reported by others (Filippov et al., 2010).
Activation of presynaptic Kv7 channels leads to a
decrease in transmitter release from cerebrocortical nerve
terminals, while inhibition causes the opposite effect (Luisi
et al., 2009), and the same holds true for SCG neurons (Her-
nandez et al., 2008). Moreover, presynaptic muscarinic
receptors have been shown to facilitate transmitter release
through inhibition of Kv7 channels (Martire et al., 2007). By
analogy, the present results suggest that the inhibition of
Kv7 channels via P2Y1 receptors is the basis for the facilita-
tion of noradrenaline release in both PC12 cells and SCG
neurons.
In hippocampal neurons, activation of P2Y1 receptors
was found to lead to inhibition of transmitter release (Rod-
rigues et al., 2005; Heinrich et al., 2008). Although the
underlying mechanisms are still obscure, endogenous as
well as recombinant P2Y1 receptors are known to mediate
inhibition of neuronal voltage-gated Ca
2+ channels (Hussl
and Boehm, 2006), and this is a prime mechanism of
presynaptic inhibition (Brown and Sihra, 2008). Recently,
P2Y1 receptors were also reported to mediate inhibition of
Ca
2+ currents in SCG neurons (Filippov et al., 2010). In the
preparation used for this study, ADP also elicits inhibition
of voltage-activated Ca
2+ channels, but this latter effect
excludes P2Y1 and is mediated only by P2Y12 receptors
(Kulick and von Kugelgen, 2002; Lechner et al., 2004). The
reasons for this discrepancy remain enigmatic, but it is
obvious that inhibition of voltage-activated Ca
2+ channels
cannot be the basis for the presynaptic facilitation described
here, but rather underlies presynaptic inhibition.
It appears puzzling that one GPCR type like P2Y1 can
mediate presynaptic facilitation or presynaptic inhibition
depending on the neuron being investigated. However, this
has also been found with other presynaptic Gq-linked
receptors, for instance with M1 muscarinic cholinoceptors:
on the one hand, M1 receptors mediate an enhancement of
noradrenaline release from sympathetic nerve terminals
through activation of PKC (Costa et al., 1993; Somogyi
et al., 1996); on the other hand, these receptors mediate
presynaptic inhibition through the depletion of membrane
phosphatidylinositol 4,5-bisphosphate via PLC and the
resulting closure of voltage-activated Ca
2+ channels (Kubista
et al., 2009). As mentioned above, P2Y1 receptors have been
reported to inhibit Kv7 channels as well as voltage-activated
Ca
2+ channels in SCG neurons, and the latter effect is deter-
mined by the presence or absence of a scaffold protein (Fil-
ippov et al., 2010). Hence, depending on the scaffold
proteins nerve terminals are endowed with, one type of
GPCR might mediate presynaptic facilitation or inhibition.
In conclusion, the present results demonstrate that ADP
controls sympathetic transmitter release not only via inhibi-
tory presynaptic P2Y12 (and maybe P2Y13) receptors but also
via facilitatory presynaptic P2Y1 receptors. The principle that
two separate GPCRs for one transmitter family, such as
adenine nucleotides, mediate opposing effects at sympathetic
nerve terminals is not unknown: noradrenaline and adrena-
line activate presynaptic a2- and b2-adrenoceptors and
thereby cause inhibition and facilitation of noradrenaline
release, respectively (Boehm and Kubista, 2002). Since nora-
drenaline and adenine nucleotides are co-transmitters in
postganglionic sympathetic neurons, the pair of inhibitory
presynaptic P2Y12 and facilitatory presynaptic P2Y1 receptors
can be viewed as a novel counterpart of the well-established
presynaptic adrenoceptors.
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